Incorporating the Voice of the Patient and Caregiver into a Multiple System Atrophy (MSA) clinical trial
Objective: To understand patient and caregiver preferences and perceptions of a proposed clinical trial design for an interventional drug targeting Multiple System Atrophy. Background: Stakeholders…Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson’s Disease
Objective: Describe 1-year efficacy outcomes from the ongoing open-label extension (OLE) phase of the BouNDless study (NCT04006210) of subcutaneous levodopa/carbidopa infusion (ND0612) for fluctuating PD…The relationship between pain threshold and striatal dopamine function in Parkinson’s Disease
Objective: This study aims to determine the relationship between pain threshold and striatal dopamine function in people with Parkinson's disease. Background: About 40-85% of Parkinson's…Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of PD and Experiences of Daily Living
Objective: Evaluate the effect of investigational ND0612 on motor signs of PD and motor experiences of daily living (m-EDL), as assessed using the MDS-UPDRS. Background:…Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study
Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience
Objective: To report on the selection of an imaging biomarker for a sub-study in a multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in…PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson’s Disease through objective measurements and patient reported outcomes – a multicenter randomized controlled trial.
Objective: The overall aim is to compare the efficacy of using wearable devices versus standard of care in improving the timeliness of referrals to evaluation…Effect of Prasinezumab on Parkinson’s Disease Motor Progression in a Long-term Open-label Extension of the PASADENA Trial
Objective: To evaluate the long-term effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part…Neurocognitive Functioning (NF) in a Patient with Idiopathic Parkinson’s Disease without Dementia (IPDWD). Subjected to Deep Brain Stimulation (DBS) and Treatment by Clinical, Functional and Advanced Neuropsychology.
Objective: To identify the Neurocognitive Functioning (NF) in a patient with IPDWD and intervened by DBS, and to analyze the impact of functional neurorehabilitation (FNR)…Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model
Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 181
- Next Page »